Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-12-31

Study Completion Date

2003-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

NCT00649181

Healthy

COMPLETED PHASE1

Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg

NCT00650195

Healthy

COMPLETED PHASE1

Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg

NCT00648271

Healthy

COMPLETED PHASE1

Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg

NCT00649116

Healthy

COMPLETED PHASE1

Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

NCT00650364

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Metolazone Tablets 2.5 mg

Group Type EXPERIMENTAL

Metolazone Tablets 2.5 mg

Intervention Type DRUG

4x2.5mg, single dose fasting

2

Zaroloxyn® Tablets 2.5 mg

Group Type ACTIVE_COMPARATOR

Zaroloxyn® Tablets 2.5 mg

Intervention Type DRUG

4x2.5mg, single dose fasting

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metolazone Tablets 2.5 mg

4x2.5mg, single dose fasting

Intervention Type DRUG

Zaroloxyn® Tablets 2.5 mg

4x2.5mg, single dose fasting

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 18 years and older
2. Sex: Male and/or non-pregnant, non-lactating female

1. Women of childbearing potential must have negative serum (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and within 72 hours prior to the start of dosing for each treatment period. An additional serum (β-HCG) pregnancy test will be performed upon completion of the study.
2. Women of childbearing potential must practice abstinence or use an acceptable form of contraception throughout the duration of the study. Acceptable forms of contraception include the following:

1. intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
2. barrier methods containing or used in conjunction with a spermicidal agent, or
3. surgical sterility (tubal ligation, oophorectomy or hysterectomy) or postmenopausal accompanied with a postmenopausal course of at least one year, as documented on the subject's medical history.
3. During the course of the study, from study screen until study exit - including the washout period, males must use a spermicide-containing barrier method of contraception to prevent the pregnancy of their sexual partner. This advice should be documented in the informed consent form.
3. Weight: At least 60 kg (132 lbs.) for men and 48 kg (106 lbs.) for women and within 15% of Ideal Body Weight (IBW), as referenced by the Table of "Desirable Weights of Adults" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
4. All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, 12-lead ECG, Hepatitis B, Hepatitis C and HIV tests, and urine drug screen including amphetamine, benzodiazepine, cannabinoid, cocaine, opiate screen, and phencyclidine) performed within 14 days of the initial dose of study medication.

Exclusion Criteria

1. Institutionalized subjects will not be used.
2. Social Habits:

1. Use of any tobacco products within one year prior to dosing.
2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
3. Ingestion of any vitamins or herbal products within the 48 hours prior to the initial dose of the study medication.
4. Any recent, significant change in dietary or exercise habits.
3. Medications:

1. Use of any medication within the last 14 days prior to the initial dose of study medication, including the use of oral contraceptives, hormone replacement therapy, and over-the-counter medications.
2. Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
4. Diseases:

1. History of any significant chronic disease and/or hepatitis.
2. History of drug and/or alcohol abuse.
3. Acute illness at the time of either the pre-study medical evaluation or dosing.
4. A positive HIV, Hepatitis B, or Hepatitis C test result.
5. Abnormal and clinically significant laboratory test results:

1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
2. Abnormal and clinically relevant ECG tracing.
6. Donation or loss of a significant volume of blood or plasma (\> 450 mL) within 28 days prior to the initial dose of study medication.
7. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
8. Allergy or hypersensitivity to metolazone, sulfonamide-derived drugs, thiazides, quinethazone or other related products.
9. History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.
10. Consumption of grapefruit or grapefruit containing products within 48 hours of drug administration.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes